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ABSTRACT The gastrointestinal microbiome plays an important role in limiting sus-
ceptibility to infection with Clostridioides difficile. To better understand the ecology
of bacteria important for C. difficile colonization resistance, we developed an experi-
mental platform to simplify complex communities of fecal bacteria through dilution
and rapidly screen for their ability to resist C. difficile colonization after challenge, as
measured by 100-fold reduction in levels of C. difficile in challenged communities.
We screened 76 simplified communities diluted from cultures of six fecal donors and
identified 24 simplified communities that inhibited C. difficile colonization in vitro.
Sequencing revealed that simplified communities were composed of 19 to 67 opera-
tional taxonomic units (OTUs) and could be partitioned into four distinct community
types. One simplified community could be further simplified from 56 to 28 OTUs
through dilution and retain the ability to inhibit C. difficile. We tested the efficacy of
seven simplified communities in a humanized microbiota mouse model. We found
that four communities were able to significantly reduce the severity of the initial C.
difficile infection and limit susceptibility to disease relapse. Analysis of fecal micro-
biomes from treated mice demonstrated that simplified communities accelerated re-
covery of indigenous bacteria and led to stable engraftment of 19 to 22 OTUs from
simplified communities. Overall, the insights gained through the identification and
characterization of these simplified communities increase our understanding of the
microbial dynamics of C. difficile infection and recovery.
IMPORTANCE Clostridioides difficile is the leading cause of antibiotic-associated diar-
rhea and a significant health care burden. Fecal microbiota transplantation is highly ef-
fective at treating recurrent C. difficile disease; however, uncertainties about the unde-
fined composition of fecal material and potential long-term unintended health
consequences remain. These concerns have motivated studies to identify new communi-
ties of microbes with a simpler composition that will be effective at treating disease.
This work describes a platform for rapidly identifying and screening new simplified com-
munities for efficacy in treating C. difficile infection. Four new simplified communities of
microbes with potential for development of new therapies to treat C. difficile disease are
identified. While this platform was developed and validated to model infection with C.
difficile, the underlying principles described in the paper could be easily modified to de-
velop therapeutics to treat other gastrointestinal diseases.
KEYWORDS Clostridioides difficile, FMT, colonization resistance, microbiome,
simplified communities
Clostridioides difficile is the most common cause of antibiotic-associated diarrhea(1–3). Estimates of annual health care costs associated with treating C. difficile
infection (CDI) in the United States range from $1 billion to $4.8 billion (4). Although
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uncomplicated infections are typically self-limiting, severe infections require treatment
(5). For approximately 25% of patients, resolution of primary infection is followed by
one or more rounds of recurrent C. difficile infection (rCDI) (6), which diminishes the
quality of life and contributes to overall health care costs (7, 8).
To cause disease, ingested C. difficile spores must germinate into vegetative cells
that produce toxins. The bile salt cholate and its derivatives stimulate C. difficile
germination, along with cogerminants glycine and other amino acids (9, 10). The
gastrointestinal microbiome plays key roles in limiting symptomatic CDI by competing
with C. difficile for nutrients (11–13), producing metabolites that inhibit C. difficile
growth (14–18), maintaining immune homeostasis (19–21), and metabolizing primary
bile salts into secondary bile salts that inhibit the growth of vegetative cells (9, 22, 23).
Antibiotic treatment leads to loss of GI microbiome diversity (24–26), is a key risk factor
for primary infection (27–30), and contributes to susceptibility to recurrent disease.
Several different therapies are currently used to treat rCDI and act to limit different
aspects of cell growth and pathogenicity. Clinical cure rates of 70% have been reported
following extended-pulsed administration of the antibiotic fidaxomicin (31). An 80%
cure rate has been reported for patients with primary and recurrent CDI treated with
bezlotoxumab, an antibody that targets C. difficile toxin B (32). Fecal microbiome
transplantation (FMT) for treatment of rCDI has reported cure rates from 44 to 100%
(33, 34). However, concern for potential adverse events (for examples, see reference 35)
motivates ongoing studies to develop alternatives to FMT to treat rCDI.
Defined community microbial therapeutics are one alternative to FMT under inves-
tigation. Previous studies have demonstrated success in administration of a consortium
of 10 (36) or 33 (37) human fecal bacteria for treatment of rCDI. Despite these advances,
no defined microbial therapeutic is currently available for treatment of CDI. One
limitation to developing microbial community therapeutics is the availability of appro-
priate models for rapid screening. We developed a coupled in vitro and in vivo platform
to screen simple microbial communities for their ability to prevent CDI. We identified
four simplified communities that limited C. difficile growth in vitro and reduced the
severity of disease in vivo. While the potential of these communities to treat disease in
humans is unknown, the approaches could be applied to identification of additional
simplified communities to treat rCDI and microbiome-linked diseases.
RESULTS
Identification of simplified communities that limit C. difficile growth in vitro. To
identify simplified communities that could suppress C. difficile, we applied a dilution/
extinction strategy (38, 39) as outlined in Fig. 1A. In this approach, undiluted fecal
communities are simplified through dilution, with abundant organisms preserved and
rare organisms randomly distributed or lost as predicted by the Poisson distribution.
Undiluted fecal communities were established in minibioreactor arrays (MBRAs)
from six individual fecal donors (D1 to D6) and allowed to stabilize (Fig. 1A). Cell density
was measured by nonselective plating and used with published operational taxonomic
unit (OTU) abundance data (40) to estimate dilutions needed to simplify communities.
Following dilution, simplified communities were stabilized in continuous culture before
challenge with 104 vegetative C. difficile cells. We measured C. difficile proliferation in
each bioreactor over time and identified nine simplified communities that lowered C.
difficile levels 10,000 times and 15 communities that decreased C. difficile levels 100
times compared to C. difficile cultivated alone in bioreactors (Fig. 1B).
CDI-resistant simplified communities separate into distinct community types.
To better understand how dilution impacted community composition, we compared
the 16S rRNA gene content between a subset of undiluted donor communities (D2 to
D4) and C. difficile-resistant simplified communities (SC1 to SC5) (Fig. 1C). The median
number of OTUs in the undiluted communities was 67; dilution reduced the median
numbers of OTUs to 50 and 42 in the simplified communities diluted 104 and 105,
respectively (Fig. 2A).
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We compared differences in community structure across simplified communities
(Fig. 2C) and used Dirichlet multinomial mixtures to identify community types and
discriminatory taxa (41) (Fig. 2D). We found that the data best partitioned into four
community types, with community type A containing SC1 and SC5 communities, while
SC2, SC3, and SC4 separated into community types B to D, respectively.
Forty-five OTUs accounted for 80% of the difference between community types in
the model (Fig. 2D). Many of these OTUs were present in all samples, but they varied
in abundance by community type. Notable features of community type A included
Bacteroides, Peptostreptococcaceae, and Lachnospiraceae OTUs. Peptostreptococcaceae
number 31, which was detected in 3 of 4 type A communities, was 100% identical to
C. difficile 16S rRNA, indicating potential experimental contamination of these commu-
nities prior to C. difficile challenge. Type B communities had higher levels of Anaero-
stipes, Clostridium_sensu_stricto, Clostridium XI, and Peptoniphilus; Akkermansia, Blautia,
Clostridium XVIII, and Enterococcus were enriched in type C communities; and Acidami-
nococcus, Bilophila, and Fusobacterium were enriched in type D communities.
Simplified communities retain the ability to suppress C. difficile when recul-
tured. We selected 17 of the 24 C. difficile-resistant SC1 to SC5 cultures for retesting
FIG 1 Identification of simplified communities that inhibit C. difficile proliferation through dilution/extinction community
assembly. (A) Overview of process to identify simplified communities. (B) Log10 C. difficile levels measured in diluted
communities on day 5 or 6 following challenge. Closed triangles, C. difficile (CD) cultured alone; open circles:, C. difficile cultured
in the presence of undiluted communities (0) and communities diluted 104 (4) and 105 (5) cultured from indicated fecal
sample donors. Solid lines represent geometric means of samples. Dashed lines demarcate inhibition of C. difficile levels by 102
and 104, with the number of samples per category indicated. (C) Schematic representation of samples generated over the
course of experiments as described in the text. Red typeface indicates samples that failed to provide protection from C. difficile
colonization at the step indicated.
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FIG 2 Comparison of microbial communities present in undiluted and simplified communities that inhibit C. difficile
growth. (A and B) The number of OTUs (A) and microbial diversity (inverse Simpson) (B) detected in undiluted communities
(squares) and communities diluted 104 (circles) and 105 (triangles) are plotted. Lines represent medians; P values of
0.05 as calculated by one-way Kruskal-Wallis testing are reported. (C) Principal-coordinate analysis (PCoA) visualization
of Bray-Curtis dissimilarities between C. difficile-resistant communities SC1 to SC5. Colors represent different SCs as
indicated; dilutions are indicated by shapes. Percent variation described by each axis is indicated in parentheses. (D)
Forty-five OTUs that most significantly contribute to partitioning of SC1 to SC5 into the indicated four community types
(A to D). The log2-transformed percent abundance of each OTU is plotted across all samples. Samples are arranged by
donor and community type as indicated at the top. Values ranged from 0.01% (yellow) to 64% (dark blue) of total
sequences as indicated; pale yellow indicates that there were no detected sequences (ND). Simplified community replicate
names are indicated in boldface, underlining indicates communities selected for reculturing as described in the text.
Table S1 contains data from all 147 OTUs that account for differences between community types.
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based on previous ability to suppress C. difficile growth (9/9 that suppressed 104;
8/24 that suppressed 102) and variation in microbiome composition (indicated by
boldface type in Fig. 2D). Simplified communities were established from frozen
stocks in triplicate MBRAs and allowed stabilization prior to challenge with C.
difficile. Thirteen of the 17 communities were able to inhibit C. difficile upon
reculturing (Fig. 1C; see also Fig. S1 in the supplemental material). Five communities
suppressed C. difficile growth 10,000-fold across all three replicates, two sup-
pressed C. difficile 100-fold across all three replicates, and six communities
suppressed C. difficile in at least one replicate (Fig. S1). We selected one replicate
from each community type described in Fig. 2D that was also able to suppress C.
difficile upon reculturing to test in a mouse model of disease. SC1A, SC2A, SC3A, and
SC4A replicates were selected; replicate names were simplified to SC1 to SC4 for
testing in mice.
SC1 and SC2 suppress CDAD. We tested SC1 to SC4 for the ability to suppress C.
difficile-associated disease (CDAD) in a humanized microbiota mouse (HMbmouse)
model of disease (42). Two positive controls were used to test for suppression of CDAD:
FMT freshly prepared from our colony of HMbmice (M-FMT) and a cryopreserved aliquot
of human FMT previously used successfully in a CDI fecal transplant program (H-FMT;
T. Savidge, personal communication). Mice were treated with antibiotics to disrupt the
microbiome and then gavaged with cells from simplified communities SC1 to SC4,
M-FMT, or H-FMT on 3 consecutive days; control mice were treated with a vehicle
(phosphate-buffered saline [PBS]) (Fig. 3A). Body mass was measured daily beginning
with the first day of gavage to test for potential toxicity of communities. Because mice
treated with SC4 exhibited 5% body mass loss from baseline prior to C. difficile
challenge (Fig. 3B), they were excluded from further analyses.
Following C. difficile challenge, mice treated with PBS exhibited a decline in body
mass (Fig. 3C) and shed C. difficile in their feces (Fig. 3E). In contrast, SC1-treated mice
maintained their body mass, with levels similar to those observed in the two positive
controls, M-FMT- and H-FMT-treated mice (Fig. 3C), and exhibited more rapid clearance
of C. difficile in feces (Fig. 3E). Trends toward reduced body mass loss in SC2- and
SC3-treated mice (Fig. 3C) and more rapid clearance of C. difficile in feces of SC2-treated
mice (Fig. 3E) were not statistically significant.
Because C. difficile was cleared more rapidly in SC1- and SC2-treated mice, we tested
whether these communities would reduce susceptibility to recurrent disease. Previ-
ously, we demonstrated that relapse could be induced through a single intraperitoneal
(i.p.) injection of clindamycin (42). Four weeks following the initial C. difficile challenge,
the majority of mice no longer shed C. difficile at detectable levels in their feces (Fig. 3E).
We treated mice with a single clindamycin i.p. injection and then measured changes in
body mass and C. difficile levels. Consistent with relapse, we observed a modest body
mass decline (Fig. 3D) and an increase of C. difficile in feces (Fig. 3E) of PBS-treated mice.
In contrast, there was a modest body mass gain, reduced shedding of C. difficile in feces,
and more rapid clearance of C. difficile in SC1- and SC2-treated mice following relapse.
M-FMT- and H-FMT-treated mice had a more modest body mass gain that was not
statistically significant from the mass of PBS-treated mice.
SC2 can be further simplified and still inhibit C. difficile growth. To test whether
either SC1 or SC2 could be further simplified, cultures were diluted to a concentration
of 250 CFU/ml (106 dilution); Poisson calculations indicated that this dilution should
reduce the complexities of SC1 and SC2 to 17 and 31 OTUs, respectively. Final simplified
communities (FS) were allowed to stabilize prior to challenge with C. difficile. Although
106 dilutions of SC1 (designated FS1A to -E) lost the ability to inhibit C. difficile, 106
dilutions of SC2 (designated FS2A to -E) continued to inhibit C. difficile growth (Fig. 4A).
C. difficile inhibition was lost when SC2 communities were diluted another 10-fold.
We analyzed the effects of further simplification on community composition and
found that the number of OTUs declined from a median of 60 in SC2 cultures to
medians of 28 and 9 in communities diluted 106 and 107 (Fig. 4B). In addition,
Simplified Communities Inhibit C. difficile
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microbial diversity decreased (Fig. 4C) and species evenness increased (Fig. 4D) with
increasing levels of dilution. The majority of OTUs lost through dilution were classified
in the order Clostridiales (Fig. 4E). We selected three final simplified communities (FS2A,
FS2B, and FS2C) to test for the ability to inhibit CDAD in HMbmice.
FS2B and FS2C suppress CDAD in HMbmice. We used the experimental approach
outlined in Fig. 3 to test final simplified communities FS2A, FS2B, and FS2C. As controls,
we administered M-FMT, SC2, and PBS. Similar to the findings in our initial study,
PBS-treated mice exhibited body mass loss following challenge with C. difficile and
weight loss was prevented by treatment with M-FMT (Fig. 4F). Treatment with SC2
prevented body mass loss, contrasting with prior results in which SC2 treatment was
partially protective. Changes in efficacy could be due to the shifts in microbial com-
position upon the reculturing of SC2 (Fig. 4E). FS2B- and FS2C-treated mice were also
protected from CDAD, whereas mice treated with community FS2A lost body mass at
a level similar to that of PBS-treated mice (Fig. 4F).
FIG 3 SC1 and SC2 suppress C. difficile-associated disease in the HMbmouse model. (A) Overview of
infection and recurrence protocol used to evaluate simplified communities and FMT treatments. Mice
were treated with a mixture of five antibiotics (5 Abx) in the drinking water for 6 days as described
previously (42). After 2 days on fresh water, mice were treated once daily with microbial communities as
indicated in panels B to E or with a vehicle (PBS) for 3 days. One day prior to C. difficile infection,
clindamycin was administered intraperitoneally (Clinda IP). On the third day of administration of
microbial communities, mice were challenged with C. difficile (Cdiff). Disease severity and levels of C.
difficile were monitored during initial infection and following induction of relapse with intraperitoneal
injection of clindamycin. In panels B to E, treatments are indicated as follows: PBS, dark blue (n  9);
HMbmouse FMT (M-FMT), magenta (n  9); human FMT (H-FMT), teal (n  9); SC1, dark purple (n  9); SC2,
light blue (n  9); SC3, violet (n  9); and SC4, black (n  8). (B) Percentage of day 2 body mass on day
0 (prior to C. difficile challenge) following 2 days of treatment with simplified communities. (C) Percentage
of day 0 body mass on day 2 following initial infection (D) Percentage of relapse day 0 body mass 2 days
following relapse. (E) Levels of C. difficile measured in the feces of treated mice on days indicated below
the graph. Boxes represent the interquartile ranges, horizontal lines indicate the medians, and vertical
lines indicate the ranges of data collected from replicate mouse samples at each time point. Significance
of differences between microbe- and PBS-treated mice in each panel were evaluated with one-way
Kruskal-Wallis testing with Dunn’s correction for multiple comparisons. P values less than 0.05 are
reported. Two mice lost from PBS (days 3 and 4) and HMbmouse FMT-treated groups (day 3) were
included in calculations until death. Mice treated with SC3 were not tested for resistance to recurrent
infection. C. difficile levels in H-FMT-treated mice were not tested on relapse day 10. Longitudinal data
collected during initial infection and relapse are plotted in Fig. S2.
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FIG 4 Identification of final simplified (FS) microbial communities that suppress C. difficile in MBRA and HMbmouse
models of CDI. (A) Plot of log10 C. difficile levels on the final day in culture with recultured SC1 (closed blue circles)
and SC2 (closed green circles) and in recultured SC1 and SC2 that were further simplified to 106-fold (open circles)
and 107-fold (open squares). Lines represent medians. (B to D) Number of OTUs (B), microbial diversity (inverse
Simpson index) (C), and species evenness (Simpson evenness index) (D) of recultured SC2 and communities diluted
106 and 107. Lines represent medians; any significant differences (P  0.05) detected in distributions of
communities as determined by one-way Kruskal-Wallis testing are reported. (E) Differences in abundance of OTUs
present above 0.1% of total sequences in at least two replicate SC2, FS2A, FS2B, or FS2C cultures. Samples are
indicated to the left of the plot; data in boldface type are from the cultures shown in panel A; the first SC2 replicate
is from the data reported in Fig. 2, and the additional SC2, FS2A, and FS2B replicates were collected from bioreactor
cultures used to gavage HMbmice in panels F to H. Yellow represents 0.01% abundance and blue repre-
sents  64% of total sequences as indicated by shading of log2-transformed relative abundance data; pale yellow
indicates that no sequences were detected (ND). In panels F to H, data were collected from HMbmice subjected to
treatment indicated as follows: PBS, dark blue (n  18); M-FMT, magenta (n  17); SC2, light blue (n  17); FS2A,
violet (n  9); FS2B, teal (n  17); and FS2C, black (n  8). Treatments were administered as described for Fig. 3A.
(F) Percentage of day 0 body mass on day 2 of infection. (G) Percentage of relapse day 0 body mass on day 2 of
relapse. (H) Log10 levels of C. difficile in mouse feces on days indicated. Boxes represent the interquartile ranges,
horizontal lines indicate the medians, and vertical lines indicate the ranges of data collected from replicate mouse
samples at each time point. Significant differences (P  0.05) in distributions of community-treated mice compared
to PBS-treated mice as determined by one-way Kruskal-Wallis testing with Dunn’s correction for multiple compar-
isons are reported. Longitudinal data from treatments shown in panels F to H are reported in Fig. S3.
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PBS-treated mice shed C. difficile in feces at similarly high levels across all time points
tested (Fig. 4H). In FS2C-treated mice, C. difficile levels were significantly lower than in
PBS-treated mice on day 1 and day 7 of infection. In SC2-treated mice, C. difficile levels
were significantly lower than in PBS-treated mice only on day 1 of infection. FS2A- and
FS2B-treated mice showed little reduction in levels of C. difficile shedding. M-FMT-
treated mice had significantly lower levels of C. difficile than PBS-treated mice at all time
points.
Following induction of relapse, we observed an 3% median reduction in body
mass in PBS-treated mice on day 2 following i.p. injection (Fig. 4G). Mice treated with
SC2, FS2B, or FS2C showed 0.5% median body mass loss, whereas FS2A-treated mice
exhibited 5% median body mass loss. M-FMT-treated mice exhibited 1% decrease
in body mass. We also observed more rapid clearance of C. difficile in FS2B- and
FS2C-treated mice (Fig. 4H).
Treatment with simplified communities has persistent effects on the fecal
microbiome. We analyzed microbial communities from mouse fecal samples on days
1, 4 or 5, and 7 and relapse days 0, 2, and 7. Sequence data obtained from mice were
pooled with bioreactor data to facilitate tracking of bacteria present in simplified
communities in treated mice. We found that sequences that clustered at 99% average
nucleotide identity (ANI) (Table S2) provided greater resolution of OTUs distinct to in
vitro-cultured simplified communities and M-FMT-treated HMbmice than sequences that
clustered at 97% ANI (Table S3). With sequences clustered at 99% ANI, 90% of OTUs
found in M-FMT-treated HMbmice were not detected in in vitro cultures and likely
represent indigenous bacteria. Similarly, 81% of OTUs found in in vitro cultures were not
detected in FMT-treated HMbmice. Subsequent analyses used OTUs that clustered
at 99% ANI.
The number of OTUs detected on day 1 following infection were 25 to 50% lower
across all treatment groups than those observed in the FMT sample collected from mice
not treated with antibiotics (Fig. 5A, HMbmouse). Treatment with M-FMT partially
restored OTU abundance and microbial diversity on day 1; full recovery to levels
observed in untreated mice was not observed until day 4 or 5 during infection. In
PBS-treated mice, the median number of OTUs detected in fecal samples increased over
time but did not return to the levels detected in untreated mice. Treatment with SC2,
FS2C, or FS2B significantly increased the number of OTUs detected on day 1 compared
to that in PBS-treated mice. Later increases in OTU abundance in FS2C-treated mice
paralleled findings for FMT-treated mice. For SC2- and FS2B-treated mice, OTU abun-
dance increased over time but not to the extent observed in FMT-treated mice. Neither
OTU abundance nor microbial diversity was significantly different between FS2A-
treated and PBS-treated mice over the first week of infection. Treatment with FMT, SC2,
FS2B, and FS2C also significantly increased microbial diversity compared to that in
PBS-treated mice (Fig. 5B).
Similarities in community composition between the baseline HMbmouse sample not
treated with antibiotics and communities in the feces of treated mice were calculated
(Fig. 5C). In M-FMT-treated mice, fecal communities had low similarities to the baseline
HMbmouse sample on day 1, but similarities increased by day 7 (Fig. 5C). In contrast,
similarities between PBS-treated mice and the baseline untreated HMbmouse sample
were significantly lower than M-FMT-treated mice through relapse day 0. Compared to
PBS-treated mice, FS2C- and SC2-treated mice exhibited an accelerated return toward
the baseline microbiome composition. FS2B-treated mice exhibited a return to baseline
microbiome that paralleled that in PBS-treated mice. In contrast, FS2A-treated mice
exhibited significantly reduced recovery of microbiome composition compared to that
of PBS-treated mice, indicating that FS2A treatment may suppress recovery of the fecal
microbiome.
Treatments shift the composition of indigenous bacteria. We identified 98 OTUs
that were significantly enriched or depleted in treatments that accelerated microbiome
recovery (FMT, FS2C, and SC2) compared to treatments with more prolonged disrup-
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tion (PBS, FS2A, and FS2B) for at least one of the time points tested (Table S3). We
focused on OTUs with the largest predicted effect sizes (linear discriminant analysis
[LDA]  3 [Fig. 6]). Three OTUs, Erysipleotrichaceae number 4, Bifidobacterium number
12, and Bacteroidales number 19, were significantly enriched in FS2C-, SC2-, and
FMT-treated mice at all time points. Erysipelotrichaceae number 8, Blautia number 31,
and Clostridium XIVa number 80 were enriched in FS2C-, SC2-, and FMT-treated mice on
day 1, whereas several Porphyromonadaceae OTUs (numbers 6, 7, 10, 75, 39, and 48) as
well as three Firmicutes OTUs (Erysipelotrichaceae number 17, Lachnospiraceae number
109, and Olsenella number 48) were enriched in FS2C-, SC2-, and FMT-treated mice at
FIG 5 Treatment with SC2 and FS2C restores microbial diversity and shifts microbiome composition
toward baseline state observed in HMbmice not treated with antibiotics. 16S rRNA gene sequence data
were obtained from bacteria present in the feces of mice treated with PBS (dark blue), M-FMT (magenta),
SC2 (light blue), FS2A (violet), FS2B (teal), or FS2C (black) on days 1, 4 or 5, and 7 following initial C.
difficile infection and days 0, 2, and 7 relative to initiation of relapse with clindamycin i.p. (For
FS2A-treated mice, 16S rRNA gene sequence data were obtained only from samples collected during
initial infection for FS2A-treated mice.) 16S rRNA sequence data were also obtained from a pooled fecal
sample collected from an HMbmice not treated with antibiotics that was used for FMT administration. (A
and B) Number of OTUs (A) and microbial diversity (inverse Simpson index) (B) measured in sample
collected from HMbmice not treated with antibiotics used for FMT administration (HMbmouse) and in
samples collected from treated mice at time points indicated below the graph. (C) Similarity to baseline
HMbmouse sample used for FMT administration measured in samples at time points indicated below
graph (similarity  1  Bray-Curtis dissimilarity). Boxes represent the interquartile ranges, horizontal lines
indicate the medians, and vertical lines indicate the ranges of data collected from replicate mouse
samples at each time point. Significance of differences in microbe-treated compared to PBS-treated
animals at each time point were evaluated with one-way Kruskal-Wallis testing with Dunn’s correction for
multiple comparisons; P values of 0.05 are reported.
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later time points. On day 1 of infection, Peptostreptococcaceae number 35 and Entero-
coccus number 28 were enriched in the feces of PBS-, FS2A-, and FS2B-treated mice,
whereas Bacteroides number 3, Bacteroides number 9, and Parabacteroides number 1
were enriched during the later stages of infection. These results demonstrate that
return toward the baseline microbiome configuration correlates with restoration of
members of multiple phyla (Bacteroidetes, Firmicutes, and Actinobacteria), whereas
continued disruption correlates with increased abundance of Bacteroides OTUs and a
Peptostreptococcaceae OTU that is likely C. difficile.
Bacteria from simplified communities persist in the feces of treated mice. We
tracked the fate of OTUs present in in vitro-cultured simplified communities over time
in mice treated with simplified communities. On day 1 following infection, 60% of
OTUs present in in vitro-cultured simplified communities could be detected in the feces
of treated mice (Fig. 7A; median OTU levels ranged from 43 to 55 OTUs). Levels of
simplified community OTUs decreased over time, with the lowest number of OTUs (16
to 23) detected on relapse day 0 (Fig. 7A). Following induction of relapse, the number
of OTUs detected from the original in vitro-cultured simplified communities increased
to 44 to 48. These results indicate that these OTUs had likely persisted below the level
of detection and reemerged when other OTUs declined following clindamycin treat-
FIG 6 Treatment with simplified communities alters recovery of indigenous microbes. We used linear
discriminant analysis effect size (LEfSe) to identify significantly enriched or depleted taxa between
treatments that accelerated microbiome recovery in Fig. 5C (M-FMT, FS2C, and SC2 [Restored]) and
treatments with more prolonged disruption (PBS, FS2A, and FS2B [Disrupted]). Independent analyses
were performed for samples on days 1, 4 or 5, and 7 and relapse day 0; OTUs with LDA values determined
by LEfSe of 3 for at least one time point are shown. Intensity of shading correlates to the log2-
transformed median percent abundance measured for the treated mice at the indicated time points, with
median abundances of 64% shaded dark blue and median values equal to 0.01% shaded dark yellow.
Samples in which sequences were below the detection limit (ND, not detected) are shaded pale yellow.
OTUs in bold typeface are indigenous to HMbmice as described in Table S2. OTUs in standard typeface
were found only in simplified communities. Blautia number 31 and Bacteroides number 3 were found in
both HMbmice and simplified communities. Peptostreptococcaceae number 35 is likely C. difficile, as the
representative sequence has 100% identity to C. difficile and abundance over the course of infection
correlates well with C. difficile levels reported in Fig. 3 and 4. The complete set of OTUs identified by LEfSe
is provided in Table S4.
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ment. OTUs that persisted over time were phylogenetically diverse (Fig. 7C). High levels
of a Phascolarctobacterium OTU (number 22) and three Bacteroides OTUs (numbers 3,
11, and 16) were detected across all community-treated mice, indicating that these
bacteria likely engrafted well.
The trend for preservation of OTUs from simplified communities followed a different
trajectory in FS2A-treated mice. The median number of FS2A OTUs detected increased
to 65 on day 4 or 5 and returned to 46 on day 7 (Fig. 7A); values were significantly
higher than those observed in mice treated with other simplified communities (Fig. 7B).
Consistent with this observation, several Bacteroides OTUs present in in vitro cultures of
all four simplified communities were only detected in the feces of FS2A-treated mice on
day 7. This increased persistence of OTUs from FS2A was also consistent with the
delayed return to baseline microbiome composition observed in these mice (Fig. 5C).
Bacteria originating from simplified communities reemerge during relapse. We
also investigated significant differences in microbiome composition between treatment
FIG 7 A subset of bacteria from simplified communities persists over time in treated mice. (A) Numbers of OTUs
in SC2 (light blue), FS2A (violet), FS2B (teal), and FS2C (black) in vitro cultures that persist over time in the feces of
treated mice. Lines represent median values at each time point, and error bars represent interquartile ranges.
Significance of differences observed between treatment groups at each time point during the initial infection (days
1, 4 or 5, and 7) were evaluated with one-way Kruskal-Wallis testing with Dunn’s correction for multiple
comparisons; P values of 0.05 are reported in panel B. (B) Data from days 4 or 5 and 7 replotted from panel A.
The box represents the interquartile range, horizontal line indicates the median, and vertical lines indicate the
range of data collected from fecal communities. (C) Log2-transformed percent abundance of OTUs that persist over
time in mice treated with SC2, FS2A, FS2B, and/or FS2C. OTUs detected in in vitro samples were designated
persistent if the median level in a treatment group on day 7 and/or relapse day 2 sample was 0.01%. Intensity
of shading correlates to the median percent abundance measured for the treated mice at the indicated time points.
OTUs in boldface type have also been detected in HMbmice as described in Table S2. Abundance data from
persistent OTUs at later times during infection (relapse days 0 and 7) and from OTUs abundant in day 0 samples
that did not persist over time in treated mice are presented in Table S5.
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groups during relapse and identified 26 OTUs that showed high levels of difference
between treatment groups during relapse. Approximately 70% of these OTUs enriched
in the feces of SC2-, FS2C-, and FS2B-treated mice on relapse day 2 likely originated
from the in vitro-cultured simplified communities (Fig. 8). Approximately 20% of OTUs
enriched on relapse day 2 were enriched on day 1 of infection, indicating that the
response to relapse was not identical to the initial disruption but shared some simi-
larities. Similar to the kinetics observed during initial infection (Fig. 6), 11 of 26 OTUs
were also significantly enriched on relapse day 7, while the remainder had decreased
in abundance.
DISCUSSION
We described a new pipeline for identifying and rigorously testing simplified
communities with the ability to protect against C. difficile infection. We identified 24
new simplified communities with the ability to inhibit C. difficile in vitro. Several of the
OTUs detected in these simplified communities were classified into families (Lachno-
spiraceae, Ruminococcaceae, Clostridiaceae, and Bacteroidaceae) and genera (Bacte-
roides, Clostridium XIVa, Anaerostipes, Coprococcus, Dorea, Roseburia, and Blautia) found
depleted in the fecal microbiomes of people who are susceptible to C. difficile and
restored following FMT treatment (43–47). In contrast, some OTUs were classified
into families less often linked to resistance to C. difficile colonization (e.g., Veillonella,
Eggerthella, Clostridium XVIII, and Acidaminococcus) or more correlated with suscepti-
bility to C. difficile infection (Enterococcus, Streptococcus, and Escherichia/Shigella). Thus,
the approach we described leads to communities distinct from those based upon
predictive ecological modeling and may provide additional insights into C. difficile
colonization resistance.
By testing simplified communities in an HMbmouse model, we determined that only
a subset of the tested communities conferred protection in vivo. Treatment with one
community, SC4, resulted in loss of body mass consistent with toxicity of one or more
FIG 8 Treatment with SC2, FS2C and FS2B led to distinct microbiome responses during disease relapse.
LEfSe was used to identify OTUs that differed significantly between treatment groups in the feces of mice
on days 2 and 7 following induction of relapse with clindamycin i.p. Independent analyses were
performed for samples on relapse days 2 and 7; OTUs with LDA values determined by LEfSe of 3 for at
least one time point are shown. The complete set of LEfSe data is shown in Table S6. Median abundance
of OTUs in in vitro SC2, FS2C, and FS2B cultures as well as all the feces of treated mice on day 1 and
relapse day 0 samples are included for comparison as described in the text.
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members of this community. Although it is not clear which community member(s) in
SC4 are toxic, SC4 contains a Bilophila OTU that could be the source of toxicity;
treatment of specific-pathogen-free (SPF) mice with Bilophila wadsworthia caused
weight loss as a result of systemic inflammation (48). Treatment with SC1, SC2, FS2B,
and FS2C significantly reduced the initial body mass loss associated with severe disease
and decreased C. difficile loads early in infection, similar to treatment with HMbmouse
FMT (M-FMT). While the magnitudes of effects varied, we observed a significant
negative correlation between C. difficile levels on day 1 of infection and body mass on
day 2 of infection (Fig. S4), with lower levels of C. difficile on day 1 predictive of reduced
body mass loss on day 2 of infection. Thus, a potential mechanism for simplified
communities to limit the severity of CDI in vivo is by delaying the germination or
outgrowth of C. difficile spores. Similar reductions in C. difficile levels on day 1 following
infection coupled to an 50% reduction in body mass loss were reported by Buffie
et al. (22) when mice were treated with a consortium of four strains. In this case, early
reductions in C. difficile levels were linked with restoration of secondary bile acid
production by Clostridium scindens, as well as unknown functions contributed by other
members of the simple community. Delaying germination or outgrowth could prevent
severe disease by altering the dynamics of the host immune response between
proinflammatory responses known to cause disease and anti-inflammatory responses
that provide protection from C. difficile epithelial damage (21, 49, 50).
Comparison of microbiome changes in the feces of mice treated with communities
that limit (FS2C, SC2, and M-FMT), partially limit (FS2B), or fail to limit (FS2A and PBS)
CDAD may explain some of the observed differences in disease progression. Treatment
with FS2C, SC2, or M-FMT significantly limited body mass loss and altered the levels of
C. difficile shedding; these communities also exhibited a more rapid return toward the
baseline microbiome configuration observed in HMbmice not treated with antibiotics.
Return toward baseline was associated with an increased abundance of members of the
indigenous microbiome, including several Porphyromonadaceae OTUs. Porphyromon-
adaceae were found to be depleted in the feces of humans and mice susceptible to C.
difficile (51, 52). Enhanced restoration of indigenous microbes observed in FS2C- and
SC2-treated mice could be due to the restoration of syntrophic interactions between
indigenous microbes and those found in simplified communities and/or suppression of
factors (i.e., C. difficile metabolism [53] and innate immune activation [54]) that promote
microbiome disruption.
Mice treated with FS2B showed limited body mass loss during initial infection but
did not show significantly altered C. difficile shedding in feces and exhibited a slower
return to baseline microbiome conditions. A return to baseline microbiome conditions
could, therefore, be important for C. difficile clearance but may not be required to
mitigate initial disease severity. Treatment with FS2A, which failed to provide protec-
tion in vivo, was associated with significantly lower levels of restoration of indigenous
microbes. Previous reports have indicated that specific probiotic formulations can delay
the return to a nondisrupted microbiome configuration due to suppression of indige-
nous microbes (55); this could also be true for FS2A-treated mice. Further studies are
needed to evaluate these hypotheses.
A subset of OTUs that originated from simplified communities persisted over time
in the feces of treated mice. While the abundance of these OTUs diminished over time,
continued colonization was demonstrated following induction of relapse. Persistence of
these simplified community OTUs likely played a key role in limiting susceptibility to
recurrent disease. One OTU of note was Phascolarctobacterium. A recent study dem-
onstrated that administration of Phascolarctobacterium species to cefoperazone-treated
mice reduces mortality, possibly by competing with C. difficile for succinate in the
disrupted gastrointestinal (GI) tract (56). Other OTUs of note include those classified as
Blautia, Ruminococcaceae, and Eisenbergiella. Colonization with members of the Rumi-
nococcaceae family and the Eisenbergiella and Blautia genera was correlated with a 60%
reduced risk for CDI in allogeneic hematopoieitic stem cell patients (57). Our results are
also consistent with a previous study of microbiome restoration following FMT in
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human patients that found a balance between engraftment of donor bacteria, persis-
tence of bacteria present in the feces of infected patients, and emergence of previously
undetected bacteria (58).
Dilution-extinction provided a rapid way to screen simplified communities for the
ability to prevent C. difficile infection. Development of diverse treatment consortia for
CDI is important, as C. difficile is known to fill different nutritional niches (59) and fecal
transplant studies indicate differential engraftment of species between patients treated
with the same fecal sample (60). However, further refinement is needed before com-
munities progress to clinical testing. Isolation of individual strains from simplified
communities prior to community reassembly and efficacy testing will ensure the
identity of the treatment consortia. In spite of these limitations, the approaches
outlined in this report represent a significant advance in the throughput of testing for
simplified communities to limit C. difficile infection and could potentially be adapted to
identify simplified communities to treat other diseases linked to microbiome disruption.
MATERIALS AND METHODS
Fecal samples, bacterial strains, and cultivation conditions. Fecal samples were provided by
anonymous subjects between the ages of 25 and 64 years who self-identified as healthy and had not
consumed antibiotics for at least 2 months or probiotics for at least 2 days prior to donation. Fecal
samples were prepared as described previously (61). The previously described ribotype 027 isolate C.
difficile 2015 was used for all experiments (61). All cultivation was performed at 37°C under an
atmosphere of 5% H2, 5% CO2, and 90% N2.
Identification of simplified communities through dilution/extinction. Fecal samples were pre-
pared and inoculated into MBRAs containing bioreactor medium 3 (BRM3) (62) as described previously
(40). Briefly, frozen fecal aliquots were thawed and used to prepare 25% (wt/vol) fecal slurries in PBS
under anaerobic conditions. After being vortexed for 5 min, the slurries were briefly centrifuged (5 min,
201  g), and clarified supernatants were used to inoculate the reactors. Fecal communities were
equilibrated for 16 h in batch growth before initiation of continuous flow (flow rate of 1.875 ml/h; 8-h
retention time). After 5 to 6 days, an aliquot was removed for determination of cell concentration
through serial dilution and plating on BRM3 agar and determination of C. difficile colonization status by
PCR as described below. (Analysis was limited to D2 to D4 and D6 communities; D1 and D5 communities
were not tested.) After 8 days, a sample was removed from each reactor and diluted to a final
concentration of 3  104 cells/ml (104 dilution) or 3  103 cells/ml (105 dilution) in BRM3. One
milliliter of each dilution was used to inoculate 5 or 6 sterile bioreactors containing 15 ml of sterile
BRM3/dilution. After 3 days under continuous flow, aliquots were removed from diluted communities for
sequencing and for cryopreservation with 15% glycerol or 7.5% dimethyl sulfoxide (DMSO). One day
later, communities were challenged with 104 C. difficile cells as described previously (61); C. difficile levels
in reactors were determined through selective plating on TCCFA agar with 20 g/ml of erythromycin and
50 g/ml of rifampin as described previously (61). For repeat cultivation, cryopreserved stocks were
thawed and 300 l was used to inoculate triplicate reactor vessels containing 15 ml of sterile BRM3.
Communities were grown in batch for 16 h and then with continuous flow for 4 days prior to challenge
with C. difficile as described above.
Analysis of C. difficile colonization status in undiluted communities D2, D3, D4, and D6. As
described above, 1-ml samples were removed from undiluted cultures on day 5 of cultivation. Cells were
concentrated by centrifugation at 20,000  g for 1 min. The supernatant was discarded and cells were
lysed by bead-beating in sterile water as previously described (40). One microliter of cell lysate was used
as the template in PCRs to detect C. difficile tcdA or bacterial 16S rRNA (broad-range 16S rRNA primers)
using previously described primers (61) added at a final concentration of 1 M to reaction mixtures
containing Denville Taq master mix otherwise formulated according to the manufacturer’s instructions.
After 35 cycles of amplification (94°C for 45 s, 55°C for 30 s, and 72°C for 1 min), 10-l volumes of
products were analyzed by agarose gel electrophoresis. Undiluted cultures had positive signals for the
16S rRNA gene as expected and no signal for C. difficile tcdA.
Further simplification of SC1 and SC2. One-milliliter stocks were thawed and used to inoculate an
empty reactor vessel. The flow of sterile BRM3 was initiated and allowed to fill the reactor at a flow rate
of 1.825 ml/h. After 3 days, cell concentrations were determined as described above. Two days later,
aliquots of cells were removed and diluted in sterile BRM3 to a final concentration of 250 cells/ml (106
dilution) or 25 cells/ml (107 dilution). One-milliliter aliquots of cells were used to inoculate 5 (106
dilution) or 6 (107 dilution) empty, sterile reactors, which were allowed to fill with sterile medium as
described above. After 2 (SC2) or 3 (SC1) days of flow, aliquots were removed for sequence analysis and
cryopreservation. One (SC1) or 15 (SC2) days later, simplified communities were challenged with 104
vegetatively growing C. difficile cells and levels of C. difficile persisting in reactors over time were
determined through selective plating.
Cultivation of simple communities for the treatment of HMbmice. Bioreactors (65 ml) were
prepared as previously described (63). Sterile, empty bioreactors were inoculated with 1 ml of thawed
stocks and allowed to fill with sterile BRM3 at a flow rate of 8.125 ml/h. Communities were cultured with
flow for 6 to 8 days before 10-ml aliquots of culture were removed, centrifuged (800  g for 10 min), and
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resuspended in 1-ml anaerobic PBS for delivery to mice. Cell densities of reactor communities were
determined through selective plating on BRM3 agar; mice received doses ranging from 5  108 to
2  109 cells freshly prepared from reactors on three subsequent days.
Preparation of HMbmouse FMT and human FMT material. Fecal samples were collected from 6- to
10 week-old male and female HMbmice (42), pooled, and resuspended in anaerobic PBS at 20% (wt/vol).
Samples were vortexed for 5 min and then centrifuged at 200  g for 2 min. Each mouse was treated with
100 l of clarified fecal slurry. The human FMT preparation was prepared as described previously (64).
Treatment of HMbmice with PBS, human FMT, HMbmouse FMT, or simplified communities.
Antibiotics (61) were administered in the drinking water to 6- to 10-week-old male and female mice
(Fig. 3A). Mice were treated with 100 l of PBS, HMbmouse FMT(M-FMT), human FMT (H-FMT), or cells from
simplified communities via orogastric gavage on three subsequent days. Clindamycin (10 mg/kg of body
weight) was administered via intraperitoneal injection. Mice were challenged with 5  104 spores of C.
difficile 2015. Three mouse experiments were performed. Mice in experiment 1 were treated with PBS,
M-FMT, H-FMT, or SC1 to SC4 (n  9 mice/treatment group except SC4 [n  8]). Mice in experiment 2
were treated with PBS, M-FMT or SC2, FS2A, or FS2B (n  9 mice/treatment group except PBS [n  10]).
Mice in experiment 3 were treated with PBS, M-FMT or SC2, FS2B, or FS2C (n  8 mice/treatment group).
In experiments 1 and 2, 100 l of inoculum from the 3rd treatment was saved for sequencing. Mouse
body mass was collected daily from days 0 to 5 following C. difficile challenge and then periodically
following resolution of severe disease as indicated in figures. Mice that lost greater than 20% body mass
from day 0 or showed signs of severe disease as previously described (42) were euthanized. Mouse body
mass was also collected on day 2 and day 1 in experiment 1. Relapse was induced 24 (experiment
3), 28 (experiment 1), or 33 (experiment 2) days following initial C. difficile infection through i.p.
administration of clindamycin (10 mg/kg). C. difficile levels in fecal samples were determined through
selective plating (experiment 1) or qPCR (experiments 2 and 3) as described previously (61) at the time
points indicated.
Analysis of microbial communities through 16S rRNA gene sequencing. Nucleic acids were
extracted from mouse fecal samples and inoculum samples using the DNeasy Powersoil HTP kit (Qiagen)
and from the further-simplified SC2 samples using the Powermag microbiome kit (MoBio). The V4 region
of the 16S rRNA gene was amplified from purified DNA or directly from lysed bioreactor samples in
triplicate using dual or single indexed primers F515/R806 as described previously (40, 65). Samples were
cleaned quantified and pooled in equimolar concentrations prior to sequencing using the Illumina MiSeq
v2 2  250 kit as described previously (40).
All sequence analysis was performed using mothur version 1.35.1. Raw sequencing reads were quality
filtered, aligned to the V4 region of Silva 16S rRNA reference release 132, preclustered into sequence
groups with 1% sequence divergence, filtered to remove chimeras with uchime, and classified with the
Bayesian classifier using rdp database version 16 (80% confidence threshold) as previously described,
with the modifications noted above (40, 66). Sequence data were then rarefied to remove those
sequences with 10 reads. Pairwise distance matrices were calculated and sequences were clustered
into OTUs with 97 and 99% ANI. OTUs were classified by the majority consensus rdp taxonomy within
the OTU. To better determine the potential identity of Peptostreptococcaceae OTU number 31 (97%
ANI) and Peptostreptococcaceae OTU number 35 (99% ANI), representative sequences from these OTUs
were compared to the nr/nt database using BLAST.
Samples were randomly subsampled to 10,000 sequences before determination of alpha and beta
diversity measures. Alpha diversity measures (number of observed OTUs, inverse Simpson diversity, and
Simpson evenness) were calculated using mothur. Principal-coordinate analysis of Bray-Curtis dissimi-
larities between communities were calculated and ordinates were visualized using the Phyloseq package
(version 1.30.0 [67]) running in R version 3.61. Simplified communities were partitioned into four
community types with Dirichlet multinomial mixtures as implemented in mothur version 1.44.0. Identi-
fication of OTUs significantly enriched between treatment groups in mouse experiments was performed
using the mothur implementation of LEfSe (40, 66). mothur was also used to calculate the Bray-Curtis
dissimilarities between treated mice and the baseline HMbmouse sample (similarity  1  Bray-Curtis
dissimilarity).
Ethics statement. Protocols for fecal sample collection were reviewed and approved by the
Institutional Review Boards of Michigan State University and Baylor College of Medicine. Animal use was
reviewed and approved by the Institutional Animal Care and Use Committee at Baylor College of
Medicine (protocol number AN-6675).
Data visualization and statistical analysis. Unless otherwise noted, data were visualized and
statistical analysis was performed using Prism v8.
Data availability. 16S rRNA gene sequence data have been deposited in the Sequence Read Archive
with accession number PRJNA632592.
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